The objective of the studies described in this proposal is to provide core virology laboratory support for AIDS Clinical Trials Group (ACTG) studies conducted by the University of Rochester AIDS Clinical Trials Unit (ACTU). It is understood that a Virology Core Laboratory would have he responsibility to conduct virologic studies for other ACTUs as well.
The specific aims of this project include: 1) performing virologic studies to measure antiretroviral effects among patients enrolled in ACTG clinical trials, 2) to store patient samples and maintain an efficient inventory system, and 3) to develop, evaluate and incorporate new techniques for measurement of virologic markers of HIV infection and disease. Techniques which are proposed for use in these studies include qualitative peripheral blood mononuclear leukocyte (PBML) cultures and measurement of p24 antigen. The applicants are certified by the ACTG's Viral Reference Laboratory (VRL) and currently perform in excess of the required 500 HIV cultures and 2,600 p24 antigen determinations per year. Additional techniques which will be employed to measure antiretroviral effects include quantitative PBML cultures, qualitative and quantitative plasma cultures, and measurement of HIV proviral DNA and virion RNA using the polymerase chain reaction (PCR). All of these techniques are established at the University of Rochester ACTU. Although not requested in the RFA, the University of Rochester ACTU is also prepared to measure HIV susceptibility to antiretroviral drugs, and, if necessary, to conduct laboratory investigations of other virus infections which commonly occur in patients who are infected with HIV.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Gupta, S K; Kitch, D; Tierney, C et al. (2015) Markers of renal disease and function are associated with systemic inflammation in HIV infection. HIV Med 16:591-8

Showing the most recent 10 out of 153 publications